Diligence memo · auto-generated · as of July 2, 2026

Vin-5 Nob Hill Therapeutics, Llc

Vin-5 Nob Hill Therapeutics, Llc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Vin-5 Nob Hill Therapeutics, Llc operates in Pharma, based in FAYETTEVILLE.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Vin-5 Nob Hill Therapeutics, Llc has raised $113K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $113K on 2016-10-26.

Most recent recorded round closed around 2016-10-26.

Valuation (modeled)modeled

Provath models Vin-5 Nob Hill Therapeutics, Llc at approximately $5.3M (range $63K–$60M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.38× the median modeled value of Pre-Seed Pharma companies in 2016–2018 (20 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 9.7 yr ago; this sector typically re-raises about every 16 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 18% of Pharma peers (310 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: vivo-TIL Therapeutics, Inc, JSK Therapeutics, Inc., Kyto Biopharma Inc, Manzara Therapeutics, Inc., Mirata BioPharma, LLC.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.